Evidence map›Paper›PMID 39365549›Full record

Observational studyAnnals of surgical oncology2025

Assessment of Outcomes by Intention-to-Treat Comparison for Locally Advanced Pancreatic Cancer: A Population-Derived Cohort Study.

Patrik Larsson, Oskar Swartling, Diana Cheraghi, Ajnon Khawaja, Kjetil Soreide, Ernesto Sparrelid, Poya Ghorbani

Abstract readObservational StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patrik LarssonDivision of Surgery and Oncology, Department of Clinical Sciences, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. patrik.larsson@ki.se.ORCID http://orcid.org/0000-0002-4726-6936
Oskar SwartlingDivision of Surgery and Oncology, Department of Clinical Sciences, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Diana CheraghiDivision of Surgery and Oncology, Department of Clinical Sciences, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Ajnon KhawajaDivision of Surgery and Oncology, Department of Clinical Sciences, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Kjetil SoreideDivision of Surgery and Oncology, Department of Clinical Sciences, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Ernesto SparrelidDivision of Surgery and Oncology, Department of Clinical Sciences, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Poya GhorbaniDivision of Surgery and Oncology, Department of Clinical Sciences, Interventions and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe overall treatment response among patients with locally advanced pancreatic cancer (LAPC) is poorly understood as most studies report solely on resected patients. We aimed to investigate the outcomes in patients with LAPC as an intention-to-treat-analysis from the time of diagnosis from a complete source population. PATIENTS AND

methodsAn observational cohort study in a population-defined region within a universal healthcare system. All consecutive patients discussed at multi-disciplinary tumour board (MDT), aged ≥ 18 years and diagnosed with LAPC were included. Exposure was set as recommended treatment by MDT (i.e. upfront surgery, neoadjuvant therapy, palliative treatment or best supportive care). Outcome measures were overall survival analysed by Kaplan-Meier survival estimates and multivariable analyses using logistic regression for odds ratios (OR) and Cox proportional hazard analysis for hazard ratios (HR).

resultsIn total, 8803 MDT events (6055 unique patients) with pancreatic disease were held during the study period. Some 1436 (24%) had pancreatic cancer, of which 162 (11%) had LAPC and 134 met the population-defined criteria. In overall survival analyses, the patients who were recommended neoadjuvant therapy (± surgery) demonstrated no significant difference to palliative chemotherapy (median 11.0 months vs. 11.8 months; p = 0.226). In multivariable analysis, adjusted OR for overall survival comparing the treatment groups was 0.27 (95% CI 0.02-3.29, p = 0.306) and Cox proportional HR 0.96 (95% CI 0.58-1.59, p = 0.865).

conclusionsIn patients with LAPC, survival was not statistically different between those recommended for attempt at neoadjuvant (± surgery) compared with those recommended palliative chemotherapy. The findings suggest that conversion/downstaging chemotherapy is successful in only a select few.

Indexed as

Intention to Treat AnalysisPancreatic NeoplasmsPatient Outcome AssessmentAdultAgedCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoadjuvant TherapyPalliative CarePancreatectomyPrognosisSurvival RateChemotherapyLocally advanced pancreatic cancerMortalityPancreatic cancerSurgerySurvival

Identifiers

PMID39365549
PMCPMC11659375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.